Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00660673
Other study ID # S187.3.005
Secondary ID 2008-001329-33
Status Completed
Phase Phase 3
First received
Last updated
Start date November 13, 2009
Est. completion date November 30, 2021

Study information

Verified date November 2022
Source AbbVie
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to provide continued access to levodopa-carbidopa intestinal gel (LCIG), to participants who have already participated in an open-label efficacy and safety study with the same treatment (Study S187.3.003 [NCT00360568] or Study S187.3.004 [NCT00335153]).


Recruitment information / eligibility

Status Completed
Enrollment 262
Est. completion date November 30, 2021
Est. primary completion date November 30, 2021
Accepts healthy volunteers No
Gender All
Age group 30 Years to 99 Years
Eligibility Inclusion Criteria: - The participant should have completed participation in Study S187.3.003 or S187.3.004; and, in the opinion of the Principal Investigator, would benefit from long-term treatment with LCIG. - For Canada, participants will be allowed to participate in the S187.3.005 study with a minimum of 6 months of exposure to LCIG in the S187.3.004 study. - The participant must be able to understand the nature of the study and must provide written informed consent prior to the conduct of any study related procedures. If the participant does not have the capacity to provide informed consent, full informed consent must be obtained from the participant's legally authorized representative. Consenting will be performed according to local regulations. Exclusion Criteria: - Medical, laboratory, psychiatric, or surgical issues deemed by the investigator to be clinically significant and which could interfere with the participant's participation in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Levodopa-Carbidopa Intestinal Gel (LCIG)
LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.
Device:
CADD-Legacy® 1400 ambulatory infusion pump
Portable infusion pump (CADD-Legacy Pump Model 1400) connected to the LCIG medication cassette reservoir.
Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)
All participants previously had a PEG-J placed in one of the prior LCIG studies.

Locations

Country Name City State
Australia Royal Adelaide Hospital /ID# 50083 Adelaide South Australia
Australia Austin Hospital /ID# 50082 Heidelberg Victoria
Australia Westmead Hospital /ID# 50081 Westmead New South Wales
Canada University of Alberta /ID# 78476 Edmonton Alberta
Canada CHUM - Notre-Dame Hospital /ID# 74513 Montréal Quebec
Canada Toronto Western Hospital /ID# 75913 Toronto Ontario
Czechia Fakultni Nemocnice u Svate Anny /ID# 50085 Brno
Czechia Fakultni nemocnice Hradec Kralove /ID# 50088 Hradec Králové
Czechia Pardubicka krajska nemocnice, a.s. Pardubice
Czechia Fakultni Nemocnice v Motole /ID# 50084 Praha
Czechia Vseobecna fakultni nemocnice v Praze /ID# 50086 Praha
Israel Tel Aviv Sourasky Medical Center /ID# 50089 Tel-Aviv
New Zealand Auckland City Hospital /ID# 50093 Auckland
New Zealand New Zealand Brain Research Institute/ID# 50090 Christchurch
New Zealand Waikato Hospital /ID# 50091 Hamilton Waikato
New Zealand Wellington Hospital /ID# 50092 Wellington
Poland Miejskie Centrum Medyczne im. dr. Karola Jonschera w Lodzi /ID# 50096 Lódz Lodzkie
Poland NZOZ Centrum Medyczne HCP /ID# 50094 Poznan Wielkopolskie
Portugal Hospitais da Universidade de Coimbra /ID# 50098 Coimbra
Portugal Hospital de Santa Maria /ID# 50099 Lisboa
Portugal Centro Hospitalar Universitario de Sao Joao, EPE /ID# 50101 Porto
Russian Federation Scientific Research Medical Complex Your Health /ID# 50104 Kazan
Russian Federation Institution of the Russian Academy of Medical Sciences Scientific Centre of Neurology /ID# 50102 Moscow
Russian Federation City Clinical Hospital #40 /ID# 50106 Saint Petersburg
Russian Federation I.P. Pavlov First St. Petersburg State Medical University /ID# 50107 Saint Petersburg
Russian Federation Military Medical Academy n.a. Kirov /ID# 50103 Saint Petersburg
Thailand King Chulalongkorn Mem Hosp /ID# 50108 Bangkok
Thailand Siriraj Hospital /ID# 50109 Bangkok
United Kingdom The Walton Centre NHS Foundation /ID# 50003 Liverpool
United Kingdom National Hospital for Neurology & Neurosurgery London
United States Georgia Regents University /ID# 49938 Augusta Georgia
United States Johns Hopkins University /ID# 49937 Baltimore Maryland
United States Univ Maryland School Medicine /ID# 49934 Baltimore Maryland
United States University of Alabama at Birmingham /ID# 49941 Birmingham Alabama
United States Bradenton Research Center, Inc /ID# 49929 Bradenton Florida
United States University of Vermont Medical Center /ID# 49912 Burlington Vermont
United States Northwestern University Feinberg School of Medicine /ID# 49944 Chicago Illinois
United States Rush University Medical Center /ID# 49930 Chicago Illinois
United States University of Cincinnati /ID# 49914 Cincinnati Ohio
United States Cleveland Clinic Main Campus /ID# 76173 Cleveland Ohio
United States The Research Center of Southern California /ID# 49928 Encinitas California
United States Colorado Neurological Institute /ID# 49927 Englewood Colorado
United States Neurologic Consultants, PA /ID# 49918 Fort Lauderdale Florida
United States The Parkinson's & Movement Disorder Institute - Fountain Valley /ID# 49915 Fountain Valley California
United States University of Florida - Archer /ID# 49935 Gainesville Florida
United States University of Florida /ID# 49922 Jacksonville Florida
United States King County Public Hospital /ID# 49917 Kirkland Washington
United States University of Kentucky Chandler Medical Center /ID# 49940 Lexington Kentucky
United States Universtiy of Southern California /ID# 49913 Los Angeles California
United States North Shore University Hospital /ID# 49932 Manhasset New York
United States Froedtert Memorial Lutheran Hospital /ID# 49924 Milwaukee Wisconsin
United States Columbia Univ Medical Center /ID# 49943 New York New York
United States The Mount Sinai Hospital /ID# 49942 New York New York
United States University of Nebraska Medical Center /ID# 49911 Omaha Nebraska
United States Charlotte Neurological Service /ID# 49916 Port Charlotte Florida
United States Raleigh Neurology Associates /ID# 49923 Raleigh North Carolina
United States Washington University-School of Medicine /ID# 49933 Saint Louis Missouri
United States Louisiana State Univ HSC /ID# 49945 Shreveport Louisiana
United States University of South Florida /ID# 49919 Tampa Florida
United States Georgetown University Hospital /ID# 49931 Washington District of Columbia
United States Wake Forest Univ HS /ID# 49939 Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
AbbVie IQVIA, formerly Quintiles

Countries where clinical trial is conducted

United States,  Australia,  Canada,  Czechia,  Israel,  New Zealand,  Poland,  Portugal,  Russian Federation,  Thailand,  United Kingdom, 

References & Publications (1)

Fernandez HH, Boyd JT, Fung VSC, Lew MF, Rodriguez RL, Slevin JT, Standaert DG, Zadikoff C, Vanagunas AD, Chatamra K, Eaton S, Facheris MF, Hall C, Robieson WZ, Benesh J, Espay AJ. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in adva — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Treatment-emergent Adverse Events Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) which started on or after the date of the first LCIG Infusion in this study and within 30 days of the date of the last PEG-J exposure.
At least possibly drug-related is defined as TEAEs assessed as having a "Possible" or "Probable" or missing relationship to study drug.
Serious AEs included any untoward medical occurrence that:
Resulted in death
Was life-threatening
Required inpatient hospitalization or prolongation of an existing hospitalization
Resulted in persistent or significant disability/incapacity
was a congenital anomaly/birth defect
The severity of all AEs was characterized as mild, moderate or severe according to the following definitions:
Mild: usually transient and do not interfere with daily activities.
Moderate: low level of inconvenience or concern to the subject, may interfere with daily activities.
Severe: events interrupt the subject's usual daily activity.
From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, with a maximum of 4217 days (11.5 years).
Secondary Number of Participants With Device Complications Device complications include complications with the pump, intestinal tube, PEG-J or stoma. From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days.
Secondary Number of Participants With Sleep Attacks Participants were asked whether they experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. If yes, participants were asked if they suffered any "bad" outcome or problem from the falling asleep event. Baseline (final assessment period of the previous open-label LCIG study) and every 6 months until final visit; median duration of treatment was 1178 days.
Secondary Number of Participants With Intense Impulsive Behavior To monitor for the development of intense impulsive behavior the Minnesota Impulsive Disorder Interview (MIDI) was administered. The MIDI is a semi-structured clinical interview assessing pathological gambling, trichotillomania, kleptomania, pyromania, intermittent explosive disorder, compulsive buying, and compulsive sexual behavior. Baseline (final assessment of the previous open-label LCIG study) and every 6 months until final visit; median duration of treatment was 1178 days.
Secondary Number of Participants Who Developed Melanoma A comprehensive assessment for the presence of melanoma was performed at least once a year by a dermatologist. Once per year during the study; median duration of treatment was 1178 days.
Secondary Number of Participants With Treatment-emergent Adverse Events of Special Interest (TE AESI) Adverse events of special interest (AESIs) were identified using standardized Medical Dictionary for Regulatory Activities (MedDRA) queries (SMQ) or company MedDRA queries (CMQs). The AESI in the following categories were identified on the basis of review of the clinical program and postmarketing observations where the treatment system is commercially available.
Procedure and device associated events
Polyneuropathy, included preferred terms in either the peripheral neuropathy or GuillainBarre syndrome standardized MedDRA query (narrow search), such as polyneuropathy, decreased vibratory sense, peripheral neuropathy, peripheral sensory neuropathy, neuralgia, demyelinating polyneuropathy, and sensory disturbance
Weight loss
Cardiovascular fatalities
Respiratory tract aspiration including aspiration pneumonia/pneumonitis.
From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, with a maximum of 4217 days (11.5 years).
Secondary Number of Participants With Any Suicidal Ideation or Behavior The Columbia-Suicide Severity Rating Scale (C-SSRS) was implemented with Protocol Amendment 3 (20 March 2012) in order to assess suicidal behavior and ideation.
Suicidal ideation includes the wish to be dead, nonspecific active suicidal thoughts, active ideation without intent to act, active ideation with some intent to act, and active ideation with specific plan or intent. Suicidal behavior includes actual attempts, interrupted attempts, aborted attempts, completed suicide, and preparatory acts or behaviors.
The number of participants with affirmative responses on the C-SSRS at any time during the treatment period is reported.
Every 6 months (beginning with implementation of Protocol Amendment 3) until final visit; median duration of treatment was 1178 days.
Secondary Number of Participants With Potentially Clinically Significant Vital Sign Values A vital sign value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding Baseline value. Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Secondary Number of Participants With Potentially Clinically Significant Hematology Laboratory Values A laboratory value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding Baseline value. Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Secondary Number of Participants With Potentially Clinically Significant Chemistry Laboratory Values A laboratory value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding baseline value.
ULN = upper limit of normal
Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Secondary Number of Participants With Vitamin Levels Outside of the Normal Range Special tests for vitamin deficiencies (folic acid, vitamin B6, vitamin B12, methylmalonic acid [MMA], and homocysteine) were implemented with Protocol Amendment 2 (27 July 2011). The number of participants with vitamin levels outside of the normal range at any time post-baseline is reported for each vitamin tested. Every 6 months (beginning with implementation of Protocol Amendment 2) until final visit; median duration of treatment was 1178 days.
Secondary Number of Participants Receiving Concomitant Anti-Parkinson's Disease Medications by Treatment Year Participants could use oral levodopa-carbidopa for scheduled or supplemental bedtime/overnight doses after the pump was disconnected for the night, or as rescue medication in case of acute deterioration caused by failure of the LCIG system such as tubes and/or the pump or the onset of an acute illness.
The initiation of additional concomitant PD medication was allowed at the discretion of the Investigator if medically indicated.
Year 1, Year 2, Year 3, Year 4, Year 5, Year 6, Year 7, Year 8, Year 9, Year 10, > Year 10 (maximum time on treatment was approximately 11.5 years).
Secondary Change in Average Daily "Off" Time Based on the Parkinson's Disease Symptom Diary at End of Treatment The PD symptom diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia.
"Off" time was defined as time when medication had worn off and was no longer providing benefit with regard to mobility, slowness, and stiffness.
PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit.
A negative change for "off" time indicates improvement. The PD diary assessment was implemented with Protocol amendment 4 (December 2013) for participants at United States (US) sites only.
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary Change in Average Daily "On" Time Without Troublesome Dyskinesia Based on the Parkinson's Disease Symptom Diary at End of Treatment The PD diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia.
"On" time is when medication is providing benefit with regard to mobility, slowness and stiffness. Dyskinesia is involuntary twisting, turning movements which are an effect of medication and occur during "on" time. Non-troublesome dyskinesia does not interfere with function or cause meaningful discomfort.
"On" time without troublesome dyskinesia is the sum of "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A positive change indicates improvement.
The PD diary was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary Change in Average Daily "On" Time With Troublesome Dyskinesia Based on the Parkinson's Disease Symptom Diary at End of Treatment The PD diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia.
"On" time is when medication is providing benefit with regard to mobility, slowness and stiffness. Dyskinesia is involuntary twisting, turning movements which are an effect of medication and occur during "on" time. Troublesome dyskinesia interferes with function or causes meaningful discomfort.
PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A positive change indicates improvement.
The PD diary was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at End of Treatment The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections:
I) Mentation, Behavior, and Mood;
II) Activities of Daily Living;
III) Motor Examinations;
IV) Complications of Therapy sections (including dyskinesias).
The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability. A negative change from Baseline indicates improvement.
The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at End of Treatment The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections:
I) Mentation, Behavior, and Mood;
II) Activities of Daily Living;
III) Motor Examinations;
IV) Complications of Therapy sections (including dyskinesias).
The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. A negative change from Baseline indicates improvement.
The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at End of Treatment The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections:
I) Mentation, Behavior, and Mood;
II) Activities of Daily Living;
III) Motor Examinations;
IV) Complications of Therapy sections (including dyskinesias).
UPDRS Part III consists of 14 questions. Questions 20 - 26 are multi-part questions in that they are evaluated separately for multiple body parts. Counting each of these assessments leads to a total of 27 answers for Part III. The UPDRS Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-Point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability. A negative change from Baseline indicates improvement.
The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary Change in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at End of Treatment The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections:
I) Mentation, Behavior, and Mood;
II) Activities of Daily Living;
III) Motor Examinations;
IV) Complications of Therapy sections (including dyskinesias).
The UPDRS total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I - III of the scale. The total score ranges from 0 - 176 with 176 representing the worst (total) disability, and 0 no disability. A negative change from Baseline indicates improvement.
The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at End of Treatment The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections:
I) Mentation, Behavior, and Mood;
II) Activities of Daily Living;
III) Motor Examinations;
IV) Complications of Therapy sections (including Dyskinesias).
The UPDRS Part IV Score is the sum of all answers to the 11 questions that comprise Part IV, 4 of which are measured on a 5-point scale (0 - 4) and 7 which are measured on a 2-point scale (0 - 1). The Part IV score ranges from 0 - 23 with higher scores associated with more disability. A negative change from Baseline indicates improvement.
The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Dyskinesia Score at End of Treatment The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections:
I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including Dyskinesias); and
The UPDRS Part IV dyskinesia Score is the sum of Questions 32 (What proportion of the waking day are dyskinesias present?), 33 (How disabling are the dyskinesias? ), and 34 (How painful are the dyskinesias?) on UPDRS Part IV, each of which are measured on a 5-point scale (0-4). The Part IV dyskinesia score ranges from 0 - 12 and higher scores are associated with more disability. A negative change from Baseline indicates improvement.
The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Secondary Change in Parkinson's Disease Questionnaire (PDQ-39) Scores at End of Treatment The PDQ-39 is a self-administered questionnaire that comprises 39 items addressing the following eight domains of health that patients consider to be adversely affected by the disease:
Mobility (e.g., fear of falling when walking) - 10 questions
Activities of daily living (e.g., difficulty cutting food) - 6 questions
Emotional well-being (e.g., feelings of isolation) - 6 questions
Stigma (e.g., social embarrassment) - 4 questions
Social support - 3 questions
Cognition - 4 questions
Communication - 3 questions
Bodily discomfort - 3 questions
Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness. The PDQ-39 summary index (range 0-100) includes responses to all 39 items. A negative change indicates improvement.
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
See also
  Status Clinical Trial Phase
Recruiting NCT02154724 - Clinical Study for Adaptive Deep Brain Stimulation (aDBS)Controlled by Intracerebral Activity in Parkinson's Disease N/A
Completed NCT02549092 - A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD) Phase 3
Completed NCT01960842 - A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications Phase 3
Completed NCT01723904 - A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3
Completed NCT01479127 - Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease Phase 2
Completed NCT03007888 - A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease Phase 2
Active, not recruiting NCT04802733 - Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease Phase 1
Completed NCT01736176 - A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease Phase 3
Completed NCT02082249 - An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications Phase 3
Completed NCT02611713 - Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease
Terminated NCT01536015 - Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction Phase 3
Completed NCT00357994 - Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Phase 3
Completed NCT00335153 - Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease Phase 3
Active, not recruiting NCT06396494 - An Automated Navigation System for Deep Brain Electrode Implantation
Recruiting NCT06195124 - A Study on the Safety and Tolerability of RGL-193 in Patients With Advanced Parkinson's Disease Early Phase 1
Completed NCT00660387 - Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Phase 3

External Links